Announcements
- Basilea berichtet über Präsentation neuer Daten zu Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2024
- Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
- Basilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des Verwaltungsrats
- Basilea shareholders approve all proposals of the board of directors at the annual general meeting
- Basilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-Wirkstoffklasse
- Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
- Basilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekannt
- Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
- Anhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus
- Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
More ▼
Key statistics
On Tuesday, Basilea Pharmaceutica AG Allschwil (PK5:BRN) closed at 40.94, -14.38% below its 52-week high of 47.81, set on Aug 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.94 |
---|---|
High | 40.94 |
Low | 40.94 |
Bid | -- |
Offer | -- |
Previous close | 40.94 |
Average volume | 65.50 |
---|---|
Shares outstanding | 13.17m |
Free float | 13.16m |
P/E (TTM) | 48.89 |
Market cap | 564.32m CHF |
EPS (TTM) | 0.8765 CHF |
Data delayed at least 15 minutes, as of May 07 2024.
More ▼